Emapunil | AC-5216 | AC5216 | CAS#226954-04-7 | MBR ligand

MedKoo Cat#: 530339 | Name: Emapunil

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Emapunil, also known as AC-5216 and XBD-173, is a novel mitochondrial benzodiazepine receptor ligand (MBR ligand). AC-5216 showed high affinity for MBRs prepared from rat whole brain (Ki 0.297 nm), rat glioma cells (IC50 3.04 nm) and human glioma cells (IC50 2.73 nm), but only negligible affinity for the other main receptors including central benzodiazepine receptors. AC-5216 produced anti-anxiety effects in the Vogel-type conflict test in rats, and in the light/dark box and social interaction tests in mice at 0.1-3, 0.003-0.01 and 0.01-0.3 mg kg(-1), p.o., respectively.

Chemical Structure

Emapunil

CAS#226954-04-7

Theoretical Analysis

MedKoo Cat#: 530339

Name: Emapunil

CAS#: 226954-04-7

Chemical Formula: C23H23N5O2

Exact Mass: 401.1852

Molecular Weight: 401.47

Elemental Analysis: C, 68.81; H, 5.77; N, 17.44; O, 7.97

Price and Availability

Size	Price	Availability
50mg	USD 250.00	2 Weeks
100mg	USD 450.00	2 Weeks
200mg	USD 750.00	2 Weeks
500mg	USD 1,650.00	2 Weeks
1g	USD 2,950.00	2 Weeks
2g	USD 5,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

AC-5216; AC 5216; AC5216; XBD-173; XBD 173; XBD173; Emapunil;

IUPAC/Chemical Name

N-benzyl-N-ethyl-2-(7-methyl-8-oxo-2-phenyl-7,8-dihydro-9H-purin-9-yl)acetamide

InChi Key

NBMBIEOUVBHEBM-UHFFFAOYSA-N

InChi Code

InChI=1S/C23H23N5O2/c1-3-27(15-17-10-6-4-7-11-17)20(29)16-28-22-19(26(2)23(28)30)14-24-21(25-22)18-12-8-5-9-13-18/h4-14H,3,15-16H2,1-2H3

SMILES Code

O=C(N(CC)CC1=CC=CC=C1)CN2C(N(C)C3=CN=C(C4=CC=CC=C4)N=C23)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 401.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Crombie GK, Palliser HK, Shaw JC, Hodgson DM, Walker DW, Hirst JJ. Neurosteroid-based intervention using Ganaxolone and Emapunil for improving stress-induced myelination deficits and neurobehavioural disorders. Psychoneuroendocrinology. 2021 Nov;133:105423. doi: 10.1016/j.psyneuen.2021.105423. Epub 2021 Sep 24. PMID: 34601389. 2: Gong J, Szego ÉM, Leonov A, Benito E, Becker S, Fischer A, Zweckstetter M, Outeiro T, Schneider A. Translocator Protein Ligand Protects against Neurodegeneration in the MPTP Mouse Model of Parkinsonism. J Neurosci. 2019 May 8;39(19):3752-3769. doi: 10.1523/JNEUROSCI.2070-18.2019. Epub 2019 Feb 22. PMID: 30796158; PMCID: PMC6510339. 3: Costa B, Da Pozzo E, Martini C. Translocator protein as a promising target for novel anxiolytics. Curr Top Med Chem. 2012;12(4):270-85. doi: 10.2174/156802612799078720. PMID: 22204481. 4: Helo Y, Searle GE, Borghese F, Abraham S, Saleem A. Specificity of translocator protein-targeted positron emission tomography in inflammatory joint disease. EJNMMI Res. 2020 Dec 7;10(1):147. doi: 10.1186/s13550-020-00736-9. PMID: 33284369; PMCID: PMC7721924. 5: Dimitrova-Shumkovska J, Krstanoski L, Veenman L. Diagnostic and Therapeutic Potential of TSPO Studies Regarding Neurodegenerative Diseases, Psychiatric Disorders, Alcohol Use Disorders, Traumatic Brain Injury, and Stroke: An Update. Cells. 2020 Apr 2;9(4):870. doi: 10.3390/cells9040870. PMID: 32252470; PMCID: PMC7226777. 6: Conti E, Grana D, Angiulli F, Karantzoulis A, Villa C, Combi R, Appollonio I, Ferrarese C; ImmunAD-Brianza Network; Tremolizzo L. TSPO Modulates Oligomeric Amyloid-β-Induced Monocyte Chemotaxis: Relevance for Neuroinflammation in Alzheimer's Disease. J Alzheimers Dis. 2023;95(2):549-559. doi: 10.3233/JAD-230239. PMID: 37574731. 7: Crombie GK, Palliser HK, Shaw JC, Hodgson DM, Walker DW, Hirst JJ. Evaluating changes in GABAergic and glutamatergic pathways in early life following prenatal stress and postnatal neurosteroid supplementation. Psychoneuroendocrinology. 2022 May;139:105705. doi: 10.1016/j.psyneuen.2022.105705. Epub 2022 Feb 26. PMID: 35276552. 8: Scholz R, Caramoy A, Bhuckory MB, Rashid K, Chen M, Xu H, Grimm C, Langmann T. Targeting translocator protein (18 kDa) (TSPO) dampens pro-inflammatory microglia reactivity in the retina and protects from degeneration. J Neuroinflammation. 2015 Nov 2;12:201. doi: 10.1186/s12974-015-0422-5. PMID: 26527153; PMCID: PMC4630900. 9: Barron AM, Higuchi M, Hattori S, Kito S, Suhara T, Ji B. Regulation of Anxiety and Depression by Mitochondrial Translocator Protein-Mediated Steroidogenesis: the Role of Neurons. Mol Neurobiol. 2021 Feb;58(2):550-563. doi: 10.1007/s12035-020-02136-5. Epub 2020 Sep 29. PMID: 32989676. 10: Cappelli A, Bini G, Valenti S, Giuliani G, Paolino M, Anzini M, Vomero S, Giorgi G, Giordani A, Stasi LP, Makovec F, Ghelardini C, Di Cesare Mannelli L, Concas A, Porcu P, Biggio G. Synthesis and structure-activity relationship studies in translocator protein ligands based on a pyrazolo[3,4-b]quinoline scaffold. J Med Chem. 2011 Oct 27;54(20):7165-75. doi: 10.1021/jm200770f. Epub 2011 Sep 26. PMID: 21916402. 11: Kim T, Pae AN. Translocator protein (TSPO) ligands for the diagnosis or treatment of neurodegenerative diseases: a patent review (2010-2015; part 1). Expert Opin Ther Pat. 2016 Nov;26(11):1325-1351. doi: 10.1080/13543776.2016.1230606. Epub 2016 Sep 13. PMID: 27607364. 12: Leva G, Klein C, Benyounes J, Hallé F, Bihel F, Collongues N, De Seze J, Mensah-Nyagan AG, Patte-Mensah C. The translocator protein ligand XBD173 improves clinical symptoms and neuropathological markers in the SJL/J mouse model of multiple sclerosis. Biochim Biophys Acta Mol Basis Dis. 2017 Dec;1863(12):3016-3027. doi: 10.1016/j.bbadis.2017.09.007. Epub 2017 Sep 9. PMID: 28899788.